Aclaris Therapeutics reports Q1 EPS (12c), consensus (12c)

Reports Q1 revenue $1.46B, consensus $3.55M. As of March 31, 2025, Aclaris had cash, cash equivalents and marketable securities of $190.5M vs. $203.9M as of December 31, 2024. The company believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operations through the first half of 2028. “We are entering into a potentially transformative multi-year period for Aclaris, with important milestones throughout our business that we believe will position us for future growth,” stated CEO Neal Walker. “Ensuring successful and timely execution of our clinical programs is our priority, and given the realities of today’s financial market environment, it’s imperative that we continue to do so in a manner that efficiently utilizes our capital. As such, we’ve announced that further global development of bosakitug – our uniquely potent anti-TSLP monoclonal antibody – in respiratory indications will be dependent on partnerships. Regarding our internal programs, we expect to initiate new clinical trials with bosakitug; ATI-2138, our highly selective oral ITK/JAK3 inhibitor; and ATI-052, our potential best-in-class bispecific anti-TSLP/IL-4R antibody, for which we recently received IND clearance from the FDA…we have the cash we believe we need to execute our plan. Our expected cash runway now extends through the first half of 2028, and we will continue to practice rigorous financial stewardship with a goal of extending our runway further by exploring additional non-dilutive opportunities.”